Report Scope
This report incorporates an in-depth analysis of CAR T-cell therapy’s current R&D status, including market estimations and trends, using 2023 as the base year and forecasting 2024 through 2029 with a compound annual growth rate (CAGR) projection. It provides an overview of the industry structure and its competitive landscape. Leading market players’ profiles, product offerings, financial information and recent market activities are provided. This report also assesses companies’ business strategies and their effect in the face of the competitive environment. The report details the CAR T-cell therapy market based on products. It reviews the historical development of CAR T-cell technology, ongoing clinical and non-clinical advances in CAR T-cell therapy and regulatory requirements. Regional analysis includes the U.S. and international markets.
Report Includes
14 data tables and 71 additional tables
Overview and analysis of the global markets for chimeric antigen receptor (CAR) T-cell therapy with an emphasis on the current status of R&D
Analyses of global market trends, with revenue data for 2022 and 2023, estimates for 2024, and projected CAGRs through 2029
Estimates of the market size and revenue growth prospects for the global CAR T-cell therapy market, along with a market share analysis by product, application, technology type and region
Facts and figures pertaining to the market dynamics, technological advances, product innovations, regulatory landscape, clinical trials, research and business consolidations, and the impact of macroeconomic factors
Insights derived from the Porter’s Five Forces model, as well as global supply chain and PESTLE analyses
Assessment of current marketed drugs, including drug development activity, R&D activity and anticipated developments, along with a look into the patent expirations in the industry
An analysis of patents, emerging trends and developments in the industry
Overview of sustainability trends and ESG developments, with emphasis on consumer attitudes, and the ESG scores and practices of leading companies
Analysis of the industry structure, including companies’ market shares and rankings, strategic alliances, M&A activity and a venture funding outlook
Profiles of leading companies, including Novartis AG, Bristol Myers Squibb Co., Gilead Sciences Inc., Johnson & Johnson Services Inc., and AstraZeneca
Companies Mentioned
Abbvie Inc.
Allogene Therapeutics
Amgen Inc.
Astrazeneca
Bluebird Bio Inc.
Bristol-myers Squibb Co.
Cellectis S.A.
Eureka Therapeutics Inc.
Gilead Sciences Inc.
Icell Gene Therapeutics Inc.
Johnson & Johnson Services Inc.
Les Laboratoires Servier
Novartis Ag
Pfizer Inc.
Protheragen Inc.
- Chapter 1 Executive Summary
- Market Outlook
- Scope of Report
- Market Summary
- Chapter 2 Market Overview
- Overview
- Market and Technology Background
- A Brief History of CAR T-Cell Therapy
- FDA Product Approvals
- Other CAR T-Cell Therapies
- Clinical Applications of CAR T-Cell Therapy
- Adoptive Cell Transfer (ACT) Technologies
- Chapter 3 Market Dynamics
- Market Dynamics
- Market Drivers
- Increasing Incidence of Cancer
- Growing Investments and Funding in CAR T-Cell Therapy Research
- Robust R&D Pipeline
- Advances in Genetic Engineering
- Market Restraints
- Complex Legislative and Regulatory Procedures
- Alternative Products from Competitors
- Market Opportunities
- Growing Significance of Precision Medicine
- Expanding Applications for CAR T-Cell Therapy
- Market Challenges
- Complex Manufacturing and Supply Chain
- Reimbursement Challenges for CAR T-Cell Therapy
- Chapter 4 Emerging Technologies and Clinical Trials
- Introduction
- Clinical Trials Being Conducted Globally
- Distribution of CAR T-Cell Clinical Trials in China
- Chapter 5 Market Segmentation Analysis
- Key Takeaways
- Segmentation Breakdown
- Global Market for CAR T-Cell Therapy, by Product
- Yescarta
- Kymriah
- Tecartus
- Abecma
- Breyanzi
- Carvykti
- Global Market for CAR T-Cell Therapy, by Indication
- Geographic Breakdown
- Global Market for CAR T-Cell Therapy, by Region
- North America
- Europe
- Asia-Pacific
- Rest of the World
- Chapter 6 Patent Review and New Developments
- Introduction
- Anticipated Increase in Patent Litigation on Customized Patient Treatments
- Company-specific Intellectual Property and Patent Information
- Amgen
- Avacta Life Sciences Ltd.
- Bluebird Bio
- Celgene Corp.
- Cellectis
- Celyad SA
- Editas Medicine Inc.
- Eureka Therapeutics Inc.
- iCell Gene Therapeutics
- Juno Therapeutics Inc. (A Celgene Co.)
- Noile-Immune Biotech
- Novartis AG
- Chapter 7 Competitive Intelligence
- Ranking of Leading Players
- Strategic Considerations
- Chapter 8 Sustainability in the CAR T-Cell Therapy Market: ESG Perspective
- Introduction to ESG
- Role of ESG in the Pharma Industry
- ESG Performance Analysis
- Environmental
- Social
- Governance
- ESG Risk Ratings
- Conclusion
- Chapter 9 Appendix
- Methodology
- Abbreviations
- References
- Company Profiles
- ABBVIE INC.
- ALLOGENE THERAPEUTICS
- AMGEN INC.
- ASTRAZENECA
- BLUEBIRD BIO INC.
- BRISTOL-MYERS SQUIBB CO.
- CELLECTIS S.A.
- EUREKA THERAPEUTICS INC.
- GILEAD SCIENCES INC.
- ICELL GENE THERAPEUTICS INC.
- JOHNSON & JOHNSON SERVICES INC.
- LES LABORATOIRES SERVIER
- NOVARTIS AG
- PFIZER INC.
- PROTHERAGEN INC.
Research Assistance
Learn how to effectively navigate the market research process to help guide your organization on the journey to success.
Download eBook